As a global leader in genomics, we continually strive to offer solutions that are not only innovative, but also accessible and always reliable. Illumina partnerships help advance genomics in numerous ways, from expanding access to next-generation sequencing (NGS) to pioneering new applications, providing funding for innovative startups, and more.
The Illumina Propel Certification Program provides your lab with the opportunity to demonstrate competency with select Illumina products through a carefully designed, standardized process. Propel Certification also offers a number of powerful benefits such as preferred pricing on selected products and services and the ability to list your service lab on Illumina.com.Learn More
With mentorship, financial support, and access to sequencers and reagents, the Illumina Accelerator is helping genomics startups launch so we can unlock the power of the genome—together.Illumina Accelerator Startup Funding
Some of our existing partnerships include:
Illumina and Roche partner to broaden the adoption of distributable next-generation sequencing-based testing in oncology.Read Press Release
Bristol-Myers Squibb and Illumina collaborate to commercialize companion diagnostics for oncology immunotherapies.Read Press Release
Illumina and Loxo Oncology partner to develop next-generation sequencing-based pan-cancer companion diagnostics.Read Press Release
Discover additional partnerships and stay informed about breaking Illumina news.
The partnership will initially focus on commercializing oncology IVD kits to support patient management and may expand in the future to include additional clinical diagnostic fields.
The partnership will result in new methods, integrating Illumina DRAGEN Pipelines and technology with the Broad’s Genome Analysis Toolkit (GATK).